Cost effectiveness of ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment

Journal of Clinical Oncology

Volumn 27, Issue 13, 2009, Pages 2185-2191

  Reed, Shelby D ^a   Li, Yanhong ^a   Anstrom, Kevin J ^a   Schulman, Kevin A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CA 163046; CAPECITABINE; IXABEPILONE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DEOXYCYTIDINE; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUOROURACIL; TAXANE; TAXOID;

ARTICLE; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEATH; DECISION MAKING; DISEASE COURSE; DRUG COST; DRUG WITHDRAWAL; FEMALE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MONOTHERAPY; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; SENSITIVITY ANALYSIS; STOCHASTIC MODEL; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; COST BENEFIT ANALYSIS; DRUG RESISTANCE; ECONOMICS; METASTASIS; MORTALITY; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; BRIDGED COMPOUNDS; COST-BENEFIT ANALYSIS; DEOXYCYTIDINE; DISEASE PROGRESSION; DRUG COSTS; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; QUALITY-ADJUSTED LIFE YEARS; TAXOIDS;

EID: 65549125891     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.19.6352     Document Type: Article

References (31)

1. Fumoleau P, Largillier R, Clippe C, et al: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer. Eur J Cancer 40:536-542, 2004 (Pubitemid 38220770)
2. Reichardt P, Von Minckwitz G, Thuss-Patience PC, et al: Multicenter phase II study of oral capecitabine (Xeloda) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 14:1227-1233, 2003 (Pubitemid 37039048)
3. Wist EA, Sommer HH, Ostenstad B, et al: Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer. Acta Oncol 43:186-189, 2004 (Pubitemid 38478906)
4. Blum JL, Dieras V, Lo Russo PM, et al: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 92:1759-1768, 2001 (Pubitemid 32952493)
5. Blum JL, Jones SE, Buzdar AU, et al: Multi-center phase II study of capecitabine in paclitaxelrefractory metastatic breast cancer. J Clin Oncol 17:485-493, 1999 (Pubitemid 29075232)
6. Zambelli A, Robustelli della Cuna FS, Ponchio L, et al: Four-day infusion of fluorouracil plus vinorelbine as salvage treatment of heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 61:241-247, 2000 (Pubitemid 30609557)
7. Rha SY, Moon YH, Jeung HC, et al: Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 90:215-221, 2005 (Pubitemid 40576834)
8. Pectasides D, Pectasides M, Farmakis D, et al: Oxaliplatin plus high-dose leucovorin and 5-fluorouracil in pretreated advanced breast cancer: A phase II study. Ann Oncol 14:537-542, 2003 (Pubitemid 41295079)
9. Zelek L, Cottu P, Tubiana-Hulin M, et al: Phase II study of oxaliplatin and fluorouracil in taxane- and anthracycline-pretreated breast cancer patients. J Clin Oncol 20:2551-2558, 2002 (Pubitemid 34525743)
10. Perez EA, Lerzo G, Pivot X, et al: Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 25:3407-3414, 2007 (Pubitemid 47310876)
11. Thomas E, Tabernero J, Fornier M, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 25:3399-3406, 2007 (Pubitemid 47310875)
12. Low JA, Wedam SB, Lee JJ, et al: Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol 23:2726-2734, 2005 (Pubitemid 46179462)
13. Thomas ES, Gomez HL, Li RK, et al: Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 25:5210-5217, 2007 (Pubitemid 350232252)
14. Lechleider RJ, Kaminskas E, Jiang X, et al: Ixabepilone in combination with capecitabine and as monotherapy for treatment of advanced breast cancer refractory to previous chemotherapies. Clin Cancer Res 14:4378-4384, 2008
15. 2006 DRG Expert: A Comprehensive Guide-book to the DRG Classification System (ed 22). Salt Lake City, UT, Ingenix, 2005
16. Centers for Medicare and Medicaid Services: PFS National Payment Amount File. http://www .cms.hhs.gov/PhysicianFeeSched/PFSNPAF/list.asp
17. Bamezai A, Melnick G: Marginal cost of emergency department outpatient visits: An update using California data. Med Care 44:835-841, 2006 (Pubitemid 44306389)
18. Centers for Medicare and Medicaid Services: Home Health Prospective Payment System (HH PPS) PC Pricer. http://www.cms.hhs.gov/PCPricer/ 05-HH.asp
19. Bureau of Labor Statistics, US Department of Labor: Consumer Price Index-All Urban Consumers. http://data.bls.gov/cgi-bin/surveymost?cu
20. Lipscomb J, Weinstein MC, Torrance GW: Time preference, in Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996, pp 214-246
21. Briggs AH, Goeree R, Blackhouse G, et al: Probabilistic analysis of cost-effectiveness models: Choosing between treatment strategies for gastroesophageal reflux disease. Med Decis Making 22: 290-308, 2002 (Pubitemid 34791317)
22. Claxton K, Sculpher M, McCabe C, et al: Probabilistic sensitivity analysis for NICE technology assessment: Not an optional extra. Health Econ 14:339-347, 2005 (Pubitemid 40514748)
23. Allison PD: Survival Analysis Using the SAS System: A Practical Guide. Cary, NC, SAS Institute, 1995
24. Meropol NJ, Schulman KA: Costs of cancer care: Issues and implications. J Clin Oncol 25:180-186, 2007 (Pubitemid 350003031)
25. Takeda AL, Jones J, Loveman E, et al: The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: A systematic review and economic evaluation. Health Technol Assess 11:1-62, 2007
26. Verma S, Ilersich AL: Population-based pharmacoeconomic model for adopting capecitabine/ docetaxel combination treatment for anthracycline- pretreated metastatic breast cancer. Oncologist 8:232-240, 2003 (Pubitemid 36648809)
27. Hillner BE, Radice D: Cost-effectiveness analysis of exemestane compared with megestrol in patients with advanced breast carcinoma. Cancer 91:484-489, 2001
28. Lindgren P, Jönsson B, Redaelli A, et al: Cost-effectiveness analysis of exemestane compared with megestrol in advanced breast cancer: A model for Europe and Australia. Pharmacoeconomics 20:101-108, 2002 (Pubitemid 34275759)
29. Nuijten M, McCormick J, Waibel F, et al: Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 3:31-39, 2000 (Pubitemid 30232946)
30. Karnon J, Johnston SR, Jones T, et al: A trial-based cost-effectiveness analysis of letrozole followed by tamoxifen versus tamoxifen followed by letrozole for postmenopausal advanced breast cancer. Ann Oncol 14:1629-1633, 2003 (Pubitemid 37455811)
31. Dranitsaris G, Verma S, Trudeau M: Cost utility analysis of first-line hormonal therapy in advanced breast cancer: Comparison of two aromatase inhibitors to tamoxifen. Am J Clin Oncol 26:289-296, 2003 (Pubitemid 36712646)